FDA Approves Ruxience, a Rituxan Biosimilar
CD20-directed antibody indicated for several cancers and other conditions.
This comprehensive, pay-for-performance approach drives clinical quality and affordability.
read
3 Ways Insurers Can Help Promote Biosimilar Adoption
The FDA Commissioner says that insurers can help biosimilar adoption by taking short-term financial losses over long-term drug savings. What else should they be doing?
Calls for “Structural Policy Changes” for Biosimilars Market
The Biosimilars Forum, in partnership with Medicines for Europe, says the U.S. can look to European policy directives to advance the biosimilars market.
5 Myths About Biosimilars—And the Facts
The falsehoods being spread about biosimilars that don’t match up with reality.
FDA Issues Biosimilar Naming Guidance
April 1, 2019
The FDA issued a lengthy statement on biosimilar naming conventions—but industry groups worry it could disincentivize biosimilar development.
The Fight to End Misleading Info on Biosimilars
April 1, 2019
Industry groups are calling for clear FDA guidance on language used by biologic originators to protect market share.
The Promise of Specialty Drugs
April 1, 2019
What the future of specialty drugs holds for healthcare.
Novel Therapies Mitigate High-Cost Rheumatoid Arthritis Treatment
March 1, 2019
The latest in RA therapies, and what you can expect from the pipeline.
The Biggest Obstacle to Cancer Biosimilar Development
March 1, 2019
Biosimilar drugs are poised to transform the cancer drug market—so why is uptake so slow?
3 Creative Ways Biologic Innovators Are Protecting Their Turf
March 1, 2019
As more biosimilar agents are approved by the FDA, biologic manufacturers are looking for unique ways to hold on to market share.
